Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,125 JPY | -0.43% | +0.88% | +1.75% |
Apr. 30 | Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion | RE |
Apr. 26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
Sales 2024 * | 4,099B 26.78B | Sales 2025 * | 4,028B 26.32B | Capitalization | 6,472B 42.29B |
---|---|---|---|---|---|
Net income 2024 * | 134B 876M | Net income 2025 * | 234B 1.53B | EV / Sales 2024 * | 2.5 x |
Net Debt 2024 * | 3,771B 24.64B | Net Debt 2025 * | 3,438B 22.46B | EV / Sales 2025 * | 2.46 x |
P/E ratio 2024 * |
46.8
x | P/E ratio 2025 * |
27.8
x | Employees | 49,095 |
Yield 2024 * |
4.56% | Yield 2025 * |
4.6% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 day | -0.43% | ||
1 week | +0.88% | ||
Current month | -0.67% | ||
1 month | +0.51% | ||
3 months | -3.60% | ||
6 months | -0.60% | ||
Current year | +1.75% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
24.44% | 15 M€ | +11.75% | ||
5.00% | 284 M€ | +25.05% | ||
3.80% | 1,552 M€ | +19.30% | ||
3.43% | 251 M€ | +13.17% | ||
3.26% | 57 M€ | +21.49% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 4,125 | -0.43% | 3,157,000 |
24-05-01 | 4,143 | -0.24% | 2,480,400 |
24-04-30 | 4,153 | +1.57% | 4,546,600 |
24-04-26 | 4,089 | -0.02% | 3,185,300 |
24-04-25 | 4,090 | -1.09% | 2,910,500 |
Delayed Quote Japan Exchange, May 02, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.75% | 42.33B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
-3.40% | 157B |
- Stock Market
- Equities
- 4502 Stock